1. Home
  2. KVUE

as of 12-12-2025 3:41pm EST

$17.36
+$0.04
+0.20%
Stocks Consumer Discretionary Specialty Chemicals Nasdaq

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.

Chart Type:
Time Range:
Founded: 2022 Country:
United States
United States
Employees: N/A City: SUMMIT
Market Cap: 39.9B IPO Year: 2023
Target Price: $20.31 AVG Volume (30 days): 37.0M
Analyst Decision: Buy Number of Analysts: 13
Dividend Yield:
4.79%
Dividend Payout Frequency: Quarterly
EPS: 0.75 EPS Growth: 35.31
52 Week Low/High: $14.02 - $25.17 Next Earning Date: 11-03-2025
Revenue: $15,006,000,000 Revenue Growth: -2.93%
Revenue Growth (this year): -0.75% Revenue Growth (next year): 2.81%

AI-Powered KVUE Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 75.96%
75.96%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Kenvue Inc. News

KVUE Breaking Stock News: Dive into KVUE Ticker-Specific Updates for Smart Investing

All KVUE News

Share on Social Networks: